nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—Glucosamine—IFNG—leprosy	0.093	0.705	CrCbGaD
Vidarabine—Grand mal convulsion—Thalidomide—leprosy	0.0411	0.0542	CcSEcCtD
Vidarabine—Glucosamine—TNF—leprosy	0.0389	0.295	CrCbGaD
Vidarabine—Burning sensation—Thalidomide—leprosy	0.0282	0.0372	CcSEcCtD
Vidarabine—Tingling sensation—Thalidomide—leprosy	0.0244	0.0321	CcSEcCtD
Vidarabine—Myocardial ischaemia—Thalidomide—leprosy	0.0244	0.0321	CcSEcCtD
Vidarabine—Numbness—Thalidomide—leprosy	0.0236	0.0311	CcSEcCtD
Vidarabine—Apnoea—Thalidomide—leprosy	0.0231	0.0305	CcSEcCtD
Vidarabine—Sensory loss—Thalidomide—leprosy	0.0226	0.0298	CcSEcCtD
Vidarabine—DPP4—blood vessel—leprosy	0.0211	0.192	CbGeAlD
Vidarabine—Atrioventricular block—Thalidomide—leprosy	0.0202	0.0266	CcSEcCtD
Vidarabine—Tinnitus—Dapsone—leprosy	0.0179	0.0236	CcSEcCtD
Vidarabine—Lightheadedness—Thalidomide—leprosy	0.0175	0.0231	CcSEcCtD
Vidarabine—Vision blurred—Dapsone—leprosy	0.0158	0.0208	CcSEcCtD
Vidarabine—Atrial fibrillation—Thalidomide—leprosy	0.015	0.0198	CcSEcCtD
Vidarabine—Cough—Dapsone—leprosy	0.0146	0.0192	CcSEcCtD
Vidarabine—Cardiac failure—Thalidomide—leprosy	0.0146	0.0192	CcSEcCtD
Vidarabine—Cerebrovascular accident—Thalidomide—leprosy	0.0145	0.0191	CcSEcCtD
Vidarabine—Affect lability—Thalidomide—leprosy	0.014	0.0184	CcSEcCtD
Vidarabine—Cardiac arrest—Thalidomide—leprosy	0.0135	0.0178	CcSEcCtD
Vidarabine—Mood swings—Thalidomide—leprosy	0.0135	0.0178	CcSEcCtD
Vidarabine—Tachycardia—Dapsone—leprosy	0.0133	0.0176	CcSEcCtD
Vidarabine—Bronchospasm—Thalidomide—leprosy	0.0121	0.0159	CcSEcCtD
Vidarabine—Pollakiuria—Thalidomide—leprosy	0.0113	0.015	CcSEcCtD
Vidarabine—Drowsiness—Thalidomide—leprosy	0.011	0.0144	CcSEcCtD
Vidarabine—Acute coronary syndrome—Thalidomide—leprosy	0.0108	0.0142	CcSEcCtD
Vidarabine—Myocardial infarction—Thalidomide—leprosy	0.0107	0.0142	CcSEcCtD
Vidarabine—Sweating—Thalidomide—leprosy	0.0105	0.0138	CcSEcCtD
Vidarabine—ADK—skin of body—leprosy	0.0101	0.0917	CbGeAlD
Vidarabine—Bradycardia—Thalidomide—leprosy	0.01	0.0132	CcSEcCtD
Vidarabine—Hypoaesthesia—Thalidomide—leprosy	0.00978	0.0129	CcSEcCtD
Vidarabine—ADA—tendon—leprosy	0.00938	0.0855	CbGeAlD
Vidarabine—Tinnitus—Thalidomide—leprosy	0.00917	0.0121	CcSEcCtD
Vidarabine—Cardiac disorder—Thalidomide—leprosy	0.00913	0.012	CcSEcCtD
Vidarabine—Mediastinal disorder—Thalidomide—leprosy	0.00886	0.0117	CcSEcCtD
Vidarabine—Arrhythmia—Thalidomide—leprosy	0.00878	0.0116	CcSEcCtD
Vidarabine—Vomiting—Dapsone—leprosy	0.00868	0.0114	CcSEcCtD
Vidarabine—Headache—Dapsone—leprosy	0.00855	0.0113	CcSEcCtD
Vidarabine—Tension—Thalidomide—leprosy	0.0084	0.0111	CcSEcCtD
Vidarabine—Dysgeusia—Thalidomide—leprosy	0.00838	0.0111	CcSEcCtD
Vidarabine—Nervousness—Thalidomide—leprosy	0.00831	0.011	CcSEcCtD
Vidarabine—Back pain—Thalidomide—leprosy	0.00828	0.0109	CcSEcCtD
Vidarabine—Nausea—Dapsone—leprosy	0.00811	0.0107	CcSEcCtD
Vidarabine—Vision blurred—Thalidomide—leprosy	0.00807	0.0106	CcSEcCtD
Vidarabine—Tremor—Thalidomide—leprosy	0.00802	0.0106	CcSEcCtD
Vidarabine—Agitation—Thalidomide—leprosy	0.00787	0.0104	CcSEcCtD
Vidarabine—Angioedema—Thalidomide—leprosy	0.00782	0.0103	CcSEcCtD
Vidarabine—ADA—testis—leprosy	0.00777	0.0708	CbGeAlD
Vidarabine—Syncope—Thalidomide—leprosy	0.00768	0.0101	CcSEcCtD
Vidarabine—ADK—tendon—leprosy	0.00767	0.0698	CbGeAlD
Vidarabine—ADA—nervous system—leprosy	0.00762	0.0694	CbGeAlD
Vidarabine—Palpitations—Thalidomide—leprosy	0.00756	0.00998	CcSEcCtD
Vidarabine—Loss of consciousness—Thalidomide—leprosy	0.00752	0.00992	CcSEcCtD
Vidarabine—Cough—Thalidomide—leprosy	0.00747	0.00985	CcSEcCtD
Vidarabine—DPP4—tendon—leprosy	0.00743	0.0677	CbGeAlD
Vidarabine—Convulsion—Thalidomide—leprosy	0.00742	0.00978	CcSEcCtD
Vidarabine—Hypertension—Thalidomide—leprosy	0.00739	0.00975	CcSEcCtD
Vidarabine—Chest pain—Thalidomide—leprosy	0.00729	0.00961	CcSEcCtD
Vidarabine—Anxiety—Thalidomide—leprosy	0.00726	0.00958	CcSEcCtD
Vidarabine—Discomfort—Thalidomide—leprosy	0.0072	0.00949	CcSEcCtD
Vidarabine—Dry mouth—Thalidomide—leprosy	0.00713	0.0094	CcSEcCtD
Vidarabine—ADORA2A—testis—leprosy	0.00707	0.0644	CbGeAlD
Vidarabine—ADORA2A—nervous system—leprosy	0.00694	0.0632	CbGeAlD
Vidarabine—Shock—Thalidomide—leprosy	0.00687	0.00906	CcSEcCtD
Vidarabine—Tachycardia—Thalidomide—leprosy	0.00682	0.00899	CcSEcCtD
Vidarabine—Hyperhidrosis—Thalidomide—leprosy	0.00675	0.00891	CcSEcCtD
Vidarabine—Hypotension—Thalidomide—leprosy	0.00653	0.00861	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Thalidomide—leprosy	0.00636	0.00839	CcSEcCtD
Vidarabine—ADK—testis—leprosy	0.00635	0.0578	CbGeAlD
Vidarabine—Paraesthesia—Thalidomide—leprosy	0.00627	0.00827	CcSEcCtD
Vidarabine—ADK—nervous system—leprosy	0.00623	0.0567	CbGeAlD
Vidarabine—Dyspnoea—Thalidomide—leprosy	0.00623	0.00821	CcSEcCtD
Vidarabine—Somnolence—Thalidomide—leprosy	0.00621	0.00819	CcSEcCtD
Vidarabine—DPP4—testis—leprosy	0.00615	0.0561	CbGeAlD
Vidarabine—DPP4—nervous system—leprosy	0.00604	0.055	CbGeAlD
Vidarabine—Pain—Thalidomide—leprosy	0.00597	0.00788	CcSEcCtD
Vidarabine—Urticaria—Thalidomide—leprosy	0.00555	0.00732	CcSEcCtD
Vidarabine—Hypersensitivity—Thalidomide—leprosy	0.00515	0.00679	CcSEcCtD
Vidarabine—Asthenia—Thalidomide—leprosy	0.00501	0.00661	CcSEcCtD
Vidarabine—Dizziness—Thalidomide—leprosy	0.00462	0.00609	CcSEcCtD
Vidarabine—Vomiting—Thalidomide—leprosy	0.00444	0.00586	CcSEcCtD
Vidarabine—Rash—Thalidomide—leprosy	0.0044	0.00581	CcSEcCtD
Vidarabine—Dermatitis—Thalidomide—leprosy	0.0044	0.0058	CcSEcCtD
Vidarabine—Headache—Thalidomide—leprosy	0.00438	0.00577	CcSEcCtD
Vidarabine—Nausea—Thalidomide—leprosy	0.00415	0.00547	CcSEcCtD
